Clinical Trial Detail

NCT ID NCT02122861
Title A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Immune Design
Indications

melanoma

lung non-small cell carcinoma

sarcoma

fallopian tube carcinoma

ovarian cancer

breast cancer

Therapies

ID-LV305

Age Groups: adult

No variant requirements are available.